Ad is loading...
CRVS
Price
$8.19
Change
-$0.33 (-3.87%)
Updated
Nov 15 closing price
109 days until earnings call
VRDN
Price
$20.14
Change
-$1.50 (-6.93%)
Updated
Nov 15 closing price
101 days until earnings call
Ad is loading...

CRVS vs VRDN

Header iconCRVS vs VRDN Comparison
Open Charts CRVS vs VRDNBanner chart's image
Corvus Pharmaceuticals
Price$8.19
Change-$0.33 (-3.87%)
Volume$2.35M
CapitalizationN/A
Viridian Therapeutics
Price$20.14
Change-$1.50 (-6.93%)
Volume$1.83M
CapitalizationN/A
CRVS vs VRDN Comparison Chart
Loading...
CRVS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
CRVS vs. VRDN commentary
Nov 17, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRVS is a Sell and VRDN is a StrongSell.

COMPARISON
Comparison
Nov 17, 2024
Stock price -- (CRVS: $8.19 vs. VRDN: $20.14)
Brand notoriety: CRVS and VRDN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRVS: 288% vs. VRDN: 136%
Market capitalization -- CRVS: $526.27M vs. VRDN: $1.6B
CRVS [@Biotechnology] is valued at $526.27M. VRDN’s [@Biotechnology] market capitalization is $1.6B. The market cap for tickers in the [@Biotechnology] industry ranges from $472.8B to $0. The average market capitalization across the [@Biotechnology] industry is $2.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRVS’s FA Score shows that 0 FA rating(s) are green whileVRDN’s FA Score has 0 green FA rating(s).

  • CRVS’s FA Score: 0 green, 5 red.
  • VRDN’s FA Score: 0 green, 5 red.
According to our system of comparison, CRVS is a better buy in the long-term than VRDN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRVS’s TA Score shows that 3 TA indicator(s) are bullish while VRDN’s TA Score has 3 bullish TA indicator(s).

  • CRVS’s TA Score: 3 bullish, 5 bearish.
  • VRDN’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, CRVS is a better buy in the short-term than VRDN.

Price Growth

CRVS (@Biotechnology) experienced а -13.33% price change this week, while VRDN (@Biotechnology) price change was -20.11% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.58%. For the same industry, the average monthly price growth was -5.90%, and the average quarterly price growth was -0.16%.

Reported Earning Dates

CRVS is expected to report earnings on Mar 06, 2025.

VRDN is expected to report earnings on Feb 26, 2025.

Industries' Descriptions

@Biotechnology (-8.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VRDN($1.6B) has a higher market cap than CRVS($526M). CRVS YTD gains are higher at: 365.341 vs. VRDN (-7.530). CRVS has higher annual earnings (EBITDA): -23.3M vs. VRDN (-224.78M). VRDN has more cash in the bank: 571M vs. CRVS (47.2M). CRVS has less debt than VRDN: CRVS (700K) vs VRDN (21M). VRDN has higher revenues than CRVS: VRDN (288K) vs CRVS (0).
CRVSVRDNCRVS / VRDN
Capitalization526M1.6B33%
EBITDA-23.3M-224.78M10%
Gain YTD365.341-7.530-4,852%
P/E RatioN/AN/A-
Revenue0288K-
Total Cash47.2M571M8%
Total Debt700K21M3%
FUNDAMENTALS RATINGS
CRVS vs VRDN: Fundamental Ratings
CRVS
VRDN
OUTLOOK RATING
1..100
349
VALUATION
overvalued / fair valued / undervalued
1..100
87
Overvalued
95
Overvalued
PROFIT vs RISK RATING
1..100
5066
SMR RATING
1..100
9597
PRICE GROWTH RATING
1..100
3443
P/E GROWTH RATING
1..100
99100
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRVS's Valuation (87) in the Pharmaceuticals Major industry is in the same range as VRDN (95) in the Biotechnology industry. This means that CRVS’s stock grew similarly to VRDN’s over the last 12 months.

CRVS's Profit vs Risk Rating (50) in the Pharmaceuticals Major industry is in the same range as VRDN (66) in the Biotechnology industry. This means that CRVS’s stock grew similarly to VRDN’s over the last 12 months.

CRVS's SMR Rating (95) in the Pharmaceuticals Major industry is in the same range as VRDN (97) in the Biotechnology industry. This means that CRVS’s stock grew similarly to VRDN’s over the last 12 months.

CRVS's Price Growth Rating (34) in the Pharmaceuticals Major industry is in the same range as VRDN (43) in the Biotechnology industry. This means that CRVS’s stock grew similarly to VRDN’s over the last 12 months.

CRVS's P/E Growth Rating (99) in the Pharmaceuticals Major industry is in the same range as VRDN (100) in the Biotechnology industry. This means that CRVS’s stock grew similarly to VRDN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRVSVRDN
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
82%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
79%
Momentum
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
84%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
85%
Bearish Trend 3 days ago
88%
Advances
ODDS (%)
Bullish Trend 7 days ago
80%
Bullish Trend 7 days ago
81%
Declines
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 3 days ago
84%
Aroon
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
85%
View a ticker or compare two or three
Ad is loading...
CRVS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MURRX23.870.28
+1.19%
MFS Utilities R2
SWASX6.500.01
+0.15%
Schwab Global Real Estate
GARJX9.86N/A
N/A
Goldman Sachs Global Rl Estt Secs Inv
BIRIX22.41-0.35
-1.54%
BlackRock Sustainable Adg Lg Cp Cr Instl
VFTAX55.83-0.89
-1.57%
Vanguard FTSE Social Index Admiral

CRVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRVS has been loosely correlated with VRDN. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if CRVS jumps, then VRDN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRVS
1D Price
Change %
CRVS100%
-3.87%
VRDN - CRVS
40%
Loosely correlated
-6.93%
PLRX - CRVS
34%
Loosely correlated
-3.27%
PRME - CRVS
34%
Loosely correlated
-6.95%
FULC - CRVS
34%
Loosely correlated
-9.49%
VCYT - CRVS
33%
Poorly correlated
-2.97%
More

VRDN and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRDN has been loosely correlated with FATE. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if VRDN jumps, then FATE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRDN
1D Price
Change %
VRDN100%
-6.93%
FATE - VRDN
50%
Loosely correlated
-2.88%
ALLO - VRDN
50%
Loosely correlated
-7.72%
CRBU - VRDN
48%
Loosely correlated
-4.78%
ABCL - VRDN
46%
Loosely correlated
-3.99%
ALEC - VRDN
46%
Loosely correlated
-17.21%
More